Abstract
To the Editor: Medium-chain acyl–coenzyme A dehydrogenase (MCAD) deficiency is the most frequently diagnosed defect in mitochondrial beta-oxidation, with a prevalence of 1 case per 15,000 persons in the United States.1 Since patients with MCAD deficiency typically present at 3 to 24 months of age with an unanticipated episode of life-threatening, hypoketotic hypoglycemia, the disease has been a prime impetus for the screening of newborns' blood with tandem mass spectroscopy, a major new public health initiative. We report on a 3-day-old neonate with lethargy, ketotic hypoglycemia, and poor feeding; incessant ventricular tachyarrhythmia developed, which progressed to episodes of torsades de . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
